Publications by authors named "Noboru Horikoshi"

Claim this Profile
P
Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
Mikihiro Kusama, Tadashi Nomizu, Kenjiro Aogi, Masataka Yoshimoto, Noboru Horikoshi

Breast Cancer· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer.
Ichiro Ichinose, Yuzo Hamada, Shoshu Mitsuyama, Emi Ishikawa, Tadashi Ikeda, Noboru Horikoshi

Chemotherapy· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.
Keiko Furukawa, Yoshinori Ito, Shunji Takahashi, Masataka Sawaki, Nobuyuki Mizunuma, Noboru Horikoshi

Breast Cancer· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
Masataka Sawaki, Yoshinori Ito, Futoshi Akiyama, Nahomi Tokudome, Rie Horii, Noboru Horikoshi

Breast Cancer· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Pharmacokinetics of S-1].
Koichi Hirata, Noboru Horikoshi, Kazusaku Tominaga, Keisuke Sohma, Koji Yamaguchi

Gan To Kagaku Ryoho· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Late phase II clinical study of KW-2307 in advanced/recurrent breast cancer patients (II)].
Takeshi Tominaga, Yasuo Nomura, Noboru Horikoshi, Shigemitsu Takashima, Morihiko Kimura

Gan To Kagaku Ryoho· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
Toshiaki Saek, Shigemitsu Takashima, Muneaki Sano, Noboru Horikoshi, Shigeto Miura

Breast Cancer· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of KW-2170, a novel pyrazoloacridone compound, in patients with malignant tumors.
Toshiaki Saeki, Kenji Eguchi, Shigemitu Takashima, Takahiko Sugiura, Toyoaki Hida, Noboru Horikoshi

Cancer Chemother Pharmacol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study.
Masataka Sawaki, Yoshinori Ito, Daigo Hashimoto, Nobuyuki Mizunuma, Shunji Takahashi, Noboru Horikoshi

Tumori· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.
Masataka Sawaki, Yoshinori Ito, Keiichiro Tada, Nobuyuki Mizunuma, Shunji Takahashi, Noboru Horikoshi

Tumori· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Kuniaki Shirao, Atsushi Ohtsu, Hideho Takada, Yasushi Mitachi, Kosei Hirakawa, Noboru Horikoshi

Cancer· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Toshiaki Saeki, Shigemitsu Takashima, Muneaki Sano, Noboru Horikoshi, Shigeto Miura

Gan To Kagaku Ryoho· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Severe infusion reaction induced by trastuzumab: a case report.
Keiichiro Tada, Yoshinori Ito, Kiyohiko Hatake, Taeko Okudaira, Jun-ichiro Watanabe, Noboru Horikoshi

Breast Cancer· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Reduction of adverse reactions of anticancer agents with altered dose and schedule].
Noboru Horikoshi

Nihon Rinsho· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation trial of ZD9331 in Japanese patients with refractory, solid malignancies.
Wasaburo Koizumi, Keisuke Aiba, Tsuneo Sasaki, Atsushi Sato, Noboru Horikoshi

Anticancer Drugs· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
Tomohiko Aihara, Yuichi Takatsuka, Kuniaki Itoh, Yasutsuna Sasaki, Noriyuki Katsumata, Noboru Horikoshi

Oncology· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer.
Kensei Yamaguchi, Masahiro Tada, Noboru Horikoshi, Toru Otani, Hiroya Takiuchi

Gastric Cancer· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I studies of nogitecan hydrochloride for Japanese.
Kunihiko Kobayashi, Mitsunori Hino, Masahiro Fukuoka, Kunio Takeuchi, Kiyoyuki Furuse, Noboru Horikoshi

Int J Clin Oncol· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
Katsuki Sugiyama, Ken Omachi, Keiichi Fujiwara, Takashi Saotome, Nobuyuki Mizunuma, Noboru Horikoshi

Cancer· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis